SFT2D3: A Potential Drug Target and Biomarker for Vesicle Transport Protein SFT2C

Target Name: SFT2D3

NCBI ID: G84826

SFT2D3

Other Name(s): Vesicle transport protein SFT2C | SFT2C_HUMAN | SFT2 domain containing 3 | vesicle transport protein SFT2C | SFT2 domain-containing protein 3

SFT2D3: A Potential Drug Target and Biomarker for Vesicle Transport Protein SFT2C

Solute transport proteins (SFTs) are a family of transmembrane proteins that play a crucial role in the regulation of intracellular fluid and solute dynamics. The protein encoded by the SFT2D3 gene is a member of this family and has been shown to be involved in vesicle transport in various cell types. As a result, SFT2D3 has potential as a drug target or biomarker.

SFT2D3 is a 21-kDa protein that localizes to the endoplasmic reticulum (ER) and is predominantly expressed in the liver and spleen. It is involved in the transport of a variety of proteins, including the protein encoded by the SLC30F1 gene, which is involved in insulin sensitivity and metabolism. SFT2D3 has also been shown to be involved in the transport of other proteins, such as the transmembrane protein ECT-2 and the cytoskeletal protein F-actinin.

SFT2D3 has been shown to play a key role in vesicle transport in various cell types. For example, it has been shown to be involved in the transport of endoplasmic vesicles to the ER, where they can be involved in protein folding and modification. have also been shown to be involved in the transport of mitochondrial vesicles to the cytosol, where they can be involved in energy metabolism.

SFT2D3 has been shown to be involved in a variety of cellular processes, including protein folding, localization, and transport. It has been shown to interact with various protein partners, including the transcription factor p300 and the protein kinase RSK. These interactions may be involved in the regulation of SFT2D3 function and the downstream targets of SFT2D3.

SFT2D3 has also been shown to be involved in the regulation of cellular processes that are important for the survival and proliferation of cells. For example, it has been shown to be involved in the regulation of cellular apoptosis, which is the process by which cells die and are removed from the body. SFT2D3 has also been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is involved in cell growth and survival.

In addition to its role in cellular processes, SFT2D3 has also been shown to be involved in the regulation of cellular interactions with the extracellular environment. For example, it has been shown to play a role in the regulation of the absorption of nutrients into the cell and the transport of waste products out of the cell.

Given the involvement of SFT2D3 in various cellular processes and its potential as a drug target, SFT2D3 is a promising candidate for further study. Research into the regulation of SFT2D3 function and its downstream targets may provide insights into the mechanisms underlying vesicle transport and other cellular processes . Additionally, the development of SFT2D3-targeting drugs or biomarkers may be a promising approach for the treatment of various diseases.

Protein Name: SFT2 Domain Containing 3

Functions: May be involved in fusion of retrograde transport vesicles derived from an endocytic compartment with the Golgi complex

The "SFT2D3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SFT2D3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets